Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
University Hospital Heidelberg
University of Florida
University Hospital Heidelberg
University Hospital Heidelberg
Eastern Cooperative Oncology Group
University of Washington
NRG Oncology
Mayo Clinic
Fred Hutchinson Cancer Center
NRG Oncology
NRG Oncology
Massachusetts General Hospital
Mayo Clinic
University of Oklahoma
Emory University
M.D. Anderson Cancer Center
Abramson Cancer Center at Penn Medicine
University of Washington
Mayo Clinic
Mayo Clinic
University of Michigan Rogel Cancer Center
Chang Gung Memorial Hospital
Loma Linda University
Mayo Clinic
Mayo Clinic
Mayo Clinic
University of Washington
Technische Universität Dresden
Odense University Hospital
Albert Einstein College of Medicine
University of Washington
University of Florida
Mayo Clinic
Abramson Cancer Center at Penn Medicine